American Research & Management Co. lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,620 shares of the company’s stock after selling 1,028 shares during the quarter. American Research & Management Co.’s holdings in Merck & Co., Inc. were worth $1,898,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. NTV Asset Management LLC raised its holdings in Merck & Co., Inc. by 22.8% in the 4th quarter. NTV Asset Management LLC now owns 24,982 shares of the company’s stock valued at $2,044,000 after acquiring an additional 4,643 shares during the period. Crawford Investment Counsel Inc. grew its holdings in Merck & Co., Inc. by 1.0% in the 4th quarter. Crawford Investment Counsel Inc. now owns 982,973 shares of the company’s stock valued at $80,407,000 after buying an additional 9,909 shares in the last quarter. Whittier Trust Co. grew its stake in shares of Merck & Co., Inc. by 2.7% in the fourth quarter. Whittier Trust Co. now owns 383,660 shares of the company’s stock valued at $31,383,000 after acquiring an additional 9,905 shares in the last quarter. Toronto Dominion Bank increased its holdings in shares of Merck & Co., Inc. by 2.9% during the fourth quarter. Toronto Dominion Bank now owns 2,742,219 shares of the company’s stock worth $143,758,000 after purchasing an additional 77,688 shares during the period. Finally, Red Spruce Capital LLC raised its holdings in Merck & Co., Inc. by 11.6% in the 1st quarter. Red Spruce Capital LLC now owns 43,864 shares of the company’s stock valued at $3,381,000 after acquiring an additional 4,553 shares in the last quarter. 72.86% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. stock traded down $0.31 during trading hours on Thursday, reaching $75.81. 247,377 shares of the company’s stock were exchanged, compared to its average volume of 11,986,551. The company has a quick ratio of 1.00, a current ratio of 1.30 and a debt-to-equity ratio of 0.90. The firm’s 50 day simple moving average is $75.36 and its 200 day simple moving average is $79.05. Merck & Co., Inc. has a twelve month low of $71.71 and a twelve month high of $87.80. The firm has a market capitalization of $191.82 billion, a PE ratio of 16.84, a PEG ratio of 1.89 and a beta of 0.43.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, February 3rd. The company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.06). The business had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.65 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.16 EPS. Analysts anticipate that Merck & Co., Inc. will post 5.9 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 7th. Stockholders of record on Monday, March 15th were given a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend was Friday, March 12th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.10%.
Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $95.92.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.
Further Reading: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.